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Abstract  
The Psychiatric Genomics Consortium (PGC) is the largest consortium in the history of psychiatry. In  the 
past decade, this global effort has delivered a rapidly increasing flow of new knowledge about the 
fundamental basis of common psychiatric disorders, particularly given its dedication to rapid progress 
and open science. The PGC has recently commenced a program of research designed to deliver 
“actionable” findings – genomic results that (a) reveal the fundamental biology, (b) inform clinical 
practice, and (c) deliver new therapeutic targets. This is the central idea of the PGC: to convert the 
family history risk factor into biologically, clinically, and therapeutically meaningful insights. The 
emerging findings suggest that we are entering into a phase of accelerated translation of genetic 
discoveries to impact psychiatric practice within a precision medicine framework.   
Introduction  
Heredity is intimately related to the history of psychiatry. Clinical observations by early physicians 
noted the tendency of mental illnesses to run in families. In the 20th century, these anecdotes were 
systematically evaluated and some were confirmed in rigorous twin, family, and adoption genetic 
epidemiological studies. This exceptional body of evidence provided a major etiological clue for the 
field: common psychiatric disorders have a moderate to strong tendency to run in families in large  part 
due to genetic inheritance (1, 2).   
We now know that these genetic effects are relatively subtle and non-deterministic: most people with 
a strong family history are not themselves affected. Moreover, most psychiatric disorders  do not 
“breed true” with increased risks spread across multiple disorders. In fact, the diverse clinical 
manifestations and variable course observed for many common psychiatric disorders are consistent 
with complex and relatively subtle genetic effects. For adult-onset common psychiatric disorders in 
particular, development is often within normal limits, and many experience relapsing/remitting 
illnesses with preservation of basic neurological function but often with some degree of erosion of 
higher components of cognition.   
In the last decade, it has become technically and economically feasible to interrogate the genome 
directly with increasing resolution and completeness. Instead of studying the heredity of psychiatric 
disorders in a general way (e.g., via studies of pedigrees, twins, or adoptees), we can now evaluate 
the genomes of cases and controls at several levels of precision quickly and inexpensively. Indeed, 
heritability itself can be assessed directly from genome-wide genetic data (3, 4).   
By carefully evaluating the successes and failures of psychiatric genetics in the past three decades, we 
now have a solid fix on how to dissect the “family history risk factor” into far more precise and 
mechanistic components. We can identify genetic variants that contribute to risk, and are moving 
toward understanding the mechanisms by which they act. The field has learned an enormous  amount, 
and is poised to make fundamental advances that could profoundly  improve understanding.   
In 2009, the Psychiatric Genomics Consortium (PGC) published three foundational papers regarding 
genome-wide association studies (GWAS) (5-7). GWAS is a genomic study design that focuses on the 
impact of common genetic variation in almost all genes in the human genome.  The  initial  PGC papers 
covered the core concepts, history, the rationale, genomic assays, statistical analysis, interpretative 
framework, and the importance of cross-disorder studies in psychiatry. Full background of the 
terminology, core concepts, and strategy of GWAS can also be found in these papers. Basic terms are 
defined in Table S1.   
 
This review provides an update on what we have learned, and puts forth an agenda for the next five 
years. A key lesson was the need for a global community effort in psychiatric genetics because the 
required samples sizes are far beyond the reach of any single group. To enable these studies, in 2007 
we formed the PGC (URLs). Our overarching goal is to deliver actionable knowledge, i.e., genetic findings 
whose biological implications can be used to improve diagnosis, develop rational  therapeutics, and craft 
mechanistic approaches to primary prevention.   
Clarity in retrospect  
A key unknown was genetic architecture, particularly the sizes of the underlying genetic effects. A 
decade ago, these were unknown and subject to considerable  speculation  with  hypotheses suggesting 
that genetic discovery for psychiatric disorders would be anywhere from highly tractable to impossible. 
If the genetic effects were few, common, and large, relative modest sample  sizes would be sufficient. A 
few early studies hinted that relatively small samples might suffice (e.g., the large effects of APOE on 
Alzheimer’s disease or CFH on age-related macular degeneration) (8, 9), and these may have led to 
expectations that gene discovery would be straight-forward.   
The power calculations are not difficult: for a given number of cases and controls (plus assumptions of 
allele frequency, genetic model, significance threshold, and power), it is easy to compute the minimum 
detectable genotypic relative risk (GRR). For example, Figure 1a shows  the  90%  power curve for a GWAS 
of 1,000 cases and 1,000 controls.   
Like most investigators in human complex disease genomics, we had limited data to allow us to narrow 
bounds on the search space. We quickly learned that optimistic assumptions of large genetic effect 
sizes for these disorders were incorrect. The initial GWAS for psychiatric disorders had sample sizes 
~1,000 cases enabling excellent power to detect GRR ≥2.5. However, these effects were not found for 
schizophrenia (10), bipolar disorder (11), major depressive disorder (12), or ADHD (13). Figure 1a also 
shows the 90% power curve for the largest published study of any psychiatric disorder (37,000 cases) 
(14), and only two of 128 independent loci had GRR ≥1.2. Compellingly, we can now demonstrate that 
common genetic variants with GRR above ~1.24 for schizophrenia can be excluded with ~100% power.   
Genetic effects that are common and large are unusual for human diseases and traits studied using 
GWAS (Figure 1b). They are occasionally found for less complex and well-measured conditions (e.g., 
infectious diseases, rare adverse drug reactions, and eye diseases). To our knowledge, the largest 
common genetic variant associations observed to date in psychiatry are for alcoholism in people of 
East Asian ancestry (GRR ~6.2) and clozapine-induced agranulocytosis (GRR ~5.3) (15, 16).   
Genetic architecture and models of disease  
Elucidation of the genetic architecture underlying these disorders is the major goal of the PGC. How 
many susceptibility or protective variants are there? What are their frequencies and effect sizes? How 
do they exert their effects? Do these variants interact with one another or with environmental risk 
factors? Crucially for biological understanding, which genes are affected by these variants?   
It is heuristically useful to consider the bookends. The extreme models are that psychiatric disorders 
are caused by (a) the cumulative impact of hundreds or thousands of common genetic variants each 
of subtle effect (common-disease/common-variant model) or (b) many different gene-disrupting 
variants of strong effect (multiple rare variant model). In the latter model, every person with a serious 
psychiatric disorder would have a strong effect variant and these would cluster in a set of genes 
important to brain development and function.   
These models were passionately debated. Some authors expressed profound hope that the multiple 
rare variant model was broadly explanatory (17-19). Others favored a common disease/common 
variant model, arguing that psychiatric phenotypes are comparatively subtle. Most investigators were 
agnostic. The PGC wished to design studies that would be informative whatever the underlying model 
(5).   
The initial strategy of the PGC  
A consistent lesson from the history of psychiatric genomics was that these are very hard problems: any 
search is going to be far more difficult than anticipated. Although we  were  hopeful  that the  initial 
GWAS might deliver insights, we created the PGC in order to hedge our bets: we needed a framework 
to aggregate data across studies with exceptional care and rigor if we were to progress. A critical step 
was to convince all groups that sharing individual data was essential – this is a foundational principle 
of the PGC and allows optimal quality control and analysis.   
Moreover, to ensure progress, an “open-science” perspective was required. Genome-wide summary 
statistics of all PGC analyses are available for widespread use (URLs), and the vast majority of PGC 
genotype data that can be deposited are available to qualified researchers in a controlled-access 
repository. We recently have made available a list of the top loci from PGC analyses (both published 
and in preparation).   
These early strategic decisions proved important: results from the first wave of psychiatric GWAS, circa 
2008, were unimpressive. Although we were careful not to hype GWAS (5, 6), some prominent 
commentators voiced strong doubts about its value – even though careful review of the early results 
showed unequivocal indications of genetic effects. The first wave studies were simply  underpowered, 
and combining studies to increase power was logical. Nevertheless, we  persisted, and a 2012 letter 
signed by 96 psychiatric genetics investigators (“Don’t give up on GWAS”) anticipated the utility of 
GWAS should sample sizes increase (20).   
To date, the PGC has published 24 main papers and 51 secondary analysis papers (Table S2). At least 
141 additional papers have made use of PGC results. Many PGC papers are highly cited, but chief among 
them is the schizophrenia Nature (14) report which ranks among  the  most  highly  cited papers in 2014. 
The PGC is among the leading genomic consortia worldwide for open science and data sharing. These 
successes are a testimony to the fact-based strategy and persistence of the PGC.  
An update  
What have we learned? We now have a sizable body of empirical results relevant to the common 
“versus” rare variant debate. All common psychiatric disorders with sufficiently large samples have a 
predominant common-disease/common variant contribution (21-23). Indeed, this is widely seen across 
human complex diseases like type 2 diabetes mellitus (24), and anthropometric traits like height (25) 
and body mass (26). Demonstrating a major role of common genetic variation on risk for human 
complex traits (including psychiatric disorders) is so widely and consistently documented that it is no 
longer particularly newsworthy.  
There is a variable contribution of rare variation of strong effect. This tends to be larger for early onset, 
severe disorders and lesser for disorders with normal-range developmental trajectories and adult 
onset (Figure 2a). However, even for psychiatric disorders with many proven examples of rare variants 
of strong effect (e.g., intellectual disability or early-onset Alzheimer’s disease), there is always a 
contribution of common variation. Rare variant studies have proven more difficult than anticipated: to 
confidently identify rare variants of strong effect in typical clinical samples requires very large sample 
sizes, perhaps as many as ~100K cases (27). The protein-coding parts  of  the genome are replete with 
inconsequential variation, and current ways to predict functional consequences are imprecise (28). 
There is a lot of noise, and the signal is sparser and weaker than anticipated.   
Table 1b shows current sample sizes and notable findings for the nine PGC working groups. 
Schizophrenia has accumulated the most data for both common and rare variation. Figure 2b shows 
significant results from GWAS, copy number variation (CNV), and exome sequencing studies (14, 29,  
30). Most findings are for common variation. Multiple rare CNVs have been implicated; most are 
multi-genic and all increase risk for several psychiatric disorders and neurological diseases (29). SETD1A 
is the only gene implicated to date by whole exome sequencing studies (30), but other such studies 
have only found hints of biological pathways by focusing on extremely rare variation (31, 32). It was 
widely anticipated that exon variation in the 0.005 to 0.01 allele frequency range would be readily 
found but this has not been observed (33), and a recent study of height required  over 700,000 subjects 
to identify loci in this range (34). In a direct comparison, common variation had 14- 28 times more 
impact on risk for schizophrenia than rare CNVs or rare exonic variation (35).   
Another major finding has been the repeated empirical documentation of important genetic overlap 
(particularly common variation) between most or all adult- and childhood-onset psychiatric disorders 
(21, 22). It is clear that psychiatric nosology has not “carved nature at  the  joints”.  Moreover, the 
common variant genetic architecture of many disorders blends into normal phenomena. For example, 
there are sizable genetic correlations of MDD with personality traits like neuroticism and easily-
assessed depressive symptom measures. Other findings suggest re- conceptualizations may be needed. 
For example, anorexia nervosa had a significant positive genetic correlation with schizophrenia, 
significant negative genetic correlations with body mass index and unfavorable metabolic measures, 
and significant positive genetic correlations with favorable metabolic factors. This pattern of findings 
suggests that the roots of anorexia may be not only psychiatric, but also metabolic in origin.   
This is an evolving area with regular increases in confident knowledge. To encourage rapid 
dissemination of results, the PGC regularly compiles an shares a list of the strongest findings for the 
disorders it studies (URLs).   
PGC, an agenda  
Attempts to understand the genetic basis of psychiatric disorders – to untangle and concretize the 
family history risk factor – have never been easy. However, by incorporating empirical results, a data-
driven and logical way forward has emerged, and it is likely that these efforts will continue to yield 
important new knowledge. Many groups are active in this area, but the PGC  has  emerged as the key 
umbrella organization for a large portion of this work. A basic description of the PGC and its core 
principles is given in Table 1a. Key technical aspects include its dedication to rigorous methodologies 
and its stance as a “mega-analysis” consortium with PGC members sharing individual-level genotype 
and phenotype data.   
With continued support from the NIMH (and new support from NIDA), the PGC recently initiated a 
program of research designed to deliver “actionable” findings, genomic results that (a) reveal the 
fundamental biology, (b) inform clinical practice, and (c) deliver new therapeutic targets. This is the 
central idea of the PGC: to convert the family history risk factor into biologically, clinically, and 
therapeutically meaningful insights. This program of research has six aims, three focused on common 
variation and three on rare variation (Table 1c).   
Aim 1 (common variation) is the core business of the PGC: to conduct progressively larger GWAS mega-
analyses and systematic cross-disorder analyses (36). Figure 3a depicts the progression of sample sizes 
with time. Our goal is for each of the nine disorder working groups to obtain GWAS data on 100,000 
cases. More information on case definitions can be found in Table S3.   
Figure 3b encapsulates experience with sample size and numbers of significant associations. Some 
disorders have a fortuitous architecture; e.g., inflammatory bowel disease obtained a considerable 
number of findings with relatively small samples. For most other complex traits, the path is slower but, 
with sufficient samples, discovery becomes linear. Figure 3c shows an idealized cartoon of the sigmoid-
like discovery process from “dead zone” to asymptote. We suggest that the goal is to get to   a “good 
enough” point where most genes are identified at least once and the majority of genes in salient 
biological processes are highlighted. This can provide an etiologic scaffold for studies that use  
other methods to identify interacting partners in gene networks and pathways that underlie 
pathogenesis. There may be on the order of 1,000 genes involved in schizophrenia (37) (for comparison, 
~13,000 genes are expressed in brain and ~2,000 at the synapse). Most PGC  groups have at least one 
association, several are accumulating moderate numbers of loci, and schizophrenia and MDD appear 
to be in the linear phase (Table 1b).   
The PGC has extended its initial efforts in three ways. First, we added four new and highly motivated 
groups (eating disorders, obsessive-compulsive disorder/Tourette syndrome, post-traumatic stress 
disorder, and substance use disorders). Provisional groups for anxiety disorders and Alzheimer’s 
disease have been formed. Second, we hope to markedly increase inclusion  of  non-European  samples 
(Figure S1). For example, the PGC is now completing a paper based on over 12,000 schizophrenia cases 
from East Asia. The post-traumatic stress disorder and substance use disorders groups are studying 
increasingly larger samples of African-Americans. The Stanley Center of the Broad Institute has launched 
major sample collection efforts for multiple severe psychiatric disorders in Africa, South America, and 
Asia.   
This work is crucial for generalizability, and it is likely that most (but not all) associations will be 
observed across the world. Finally, the PGC has engaged academic and industry experts to understand 
the therapeutic salience of the findings (38). Indeed, the empirical targets of antipsychotic medications 
are markedly enriched for the results of schizophrenia GWAS and this enrichment became clearer with 
increasing sample sizes, as has the potential pharmacological relevance of calcium channels for 
psychiatry (39). The design of rational therapeutics has been an elusive goal for psychiatric indications, 
and improved genomic knowledge is  a  pre-competitive activity that can make novel drug discovery 
more efficient (40).   
 
Aim 2 (common variation) concerns the analysis of  genetic risk scores  (GRS). For a  complex disease  or 
trait, GRS is a single, normally distributed variable that captures the cumulative effect of risk alleles 
inherited by an individual (e.g., for schizophrenia, bipolar disorder, or body mass index). Computing a 
GRS requires a training set (i.e., GWAS results) and genome-wide genotypes on independent test 
subjects (e.g., a population cohort or participants in a clinical trial). The PGC has made training sets 
publicly available for multiple disorders (URLs). This allows researchers  to  compute GRS for whatever 
use they deem appropriate. GRS are not yet sufficiently discriminating to be useful clinically (14) but 
are among the first demonstrably valid biomarkers for psychiatric disorders. GRS derived from PGC 
results have been widely used in  psychiatric  research  for generating patient strata, exploring 
diagnostic boundaries, identifying cognitive and behavioral correlates of genetic risk that predate 
clinical disorders, and evaluating the validity of putative cognitive or imaging phenotypes (41). Even 
social scientists have embraced the approach, seeing opportunities to study how genetic factors 
interact with the social environment to influence health and broader outcomes (42).   
The PGC will systematically evaluate GRS in three contexts: (a) Development: use data from large 
longitudinal cohorts to evaluate the developmental effects of GRS; (b) Clinical symptoms: analyze 
relationship between clinical descriptors and GRS to understand clinical relevance; and (c) analyze GRS 
by environment interactions in epidemiological samples.   
Aim 3 (common variation) will use GWAS results to estimate pairwise genetic correlations among all 
PGC disorders with all obtainable CNS-relevant diseases and quantitative traits (e.g., epilepsy, 
neuroimaging, personality, IQ). We will develop a comprehensive portrait of genetic influences across 
a broad set of brain phenotypes with the intention of improving nosology.   
For example, the pairwise genetic correlations (URLs) among anorexia nervosa, ADHD, ASD, bipolar 
disorder, MDD, and schizophrenia are almost all significant and positive (the exceptions are all 
correlations of ASD and anorexia nervosa-ADHD, certainly influenced by small  sample sizes) (43). This 
suggests that the common variant genetic architectures – the fundamental liability to these disorders 
– overlap importantly. After evaluating the disorder-level genetic correlations (22), we will 
systematically expand our queries to encompass within disorder genetic correlations (e.g., male vs 
female, early vs later onset) as well as genetic correlations with putative components (e.g., cognition, 
personality, body mass).   
Aim 4 (rare variation) will continue the PGC’s CNV efforts (29). The PGC CNV group has created a 
pipeline to call CNVs from the initial intensity files using multiple algorithms followed by careful quality 
control and analysis. The initial schizophrenia paper has been published, and this group is now working 
on bipolar disorder, ADHD, and PTSD, and will include more groups with time.   
Aim 5 (rare variation) is a “cheap-seq” aim. We will conduct inexpensive (~$50/subject) schizophrenia-
focused sequencing of 200 genes in 20,000 subjects. Genes will be selected based on all available 
sequencing results. For 200 genes, we will increase power far more cost-effectively than whole exome 
(10x cheaper) or whole genome sequencing (25x cheaper) in the same time frame. We propose an 
efficient and affordable way to markedly increase sample sizes for the most  promising loci in a new 
sample of 20,000 subjects.   
Aim 6 (rare variation) will systematically evaluate ~100 large pedigrees to search for genetic variants 
of large effect. We have engaged the large network of PGC clinicians in this task. Most experienced 
clinicians have encountered unusual pedigrees with high concentrations of severe psychiatric 
disorders. For example, one pedigree has >100 individuals with a severe psychiatric  disorder and eight 
pedigrees have ≥20 affected individuals. Other pedigrees are from genetic isolates where inter- 
pedigree marriage is common. Still other pedigrees have extensive comorbidity with intellectual 
disability and epilepsy. No one  has systematically and comprehensively evaluated a large collection  of 
densely affected pedigrees using comprehensive genomic assays (karyotyping,  identity-by- descent, 
CNVs, whole genome sequencing, and GRS) combined with a rigorous statistical framework.   
Actionability. For the common variant aims, Aim 1 is of biological, clinical, and therapeutic relevance. 
Aim 2 and Aim 3 are important clinically and for nosology. Of the rare variant aims, all are important 
biologically and therapeutically (given their potential to identify single genes whose mutational 
disruption carries high risk).   
Issues in the process of being solved  
Empirical results from psychiatric genomics have begun to answer many questions. However, we point 
to two major unresolved issues. First, many GWAS signals are complex. Exactly how these connect to 
specific genes to enable precise experimentation is solvable but requires functional genomic or 
functional cellular data. Figure 4a shows the CACNA1C intronic association for schizophrenia; a 
subsequent study suggested that these SNPs interact with a regulatory element for CACNA1C (44). 
Figure 4b  depicts the  region surrounding DRD2  (which encodes  the  protein targeted by most 
antipsychotics). This association has been functionally connected to the gene via DNA-DNA interactions 
(45). Figure 4c shows a multigenic region – the association region covers many genes (most of which are 
expressed in brain) that have been associated with multiple human traits. Finally, Figure 4d depicts an 
intergenic region that is associated with schizophrenia but not near a known protein-coding gene.   
These are typical for GWAS results, identifying relatively broad loci with multiple genome-wide 
significant markers. Although localization is imprecise, the associated genomic regions are clearly 
informative as they implicate salient biological pathways (46) and increasingly specific genomic 
features (47). Full elucidation requires functional genomic data generated from relevant cell types 
including gene expression (48), DNA-DNA looping (45), and epigenomics (49). To facilitate this work, 
the NIMH has funded the psychENCODE consortium (49) to conduct an array of functional genomic 
assays on brain tissue from people with severe psychiatric disorders and controls (URLs).   
Second, the extant cross-disorder studies of psychiatric disorders show non-trivial genetic overlap 
between most or all disorders. The results clearly show that our diagnostic categories do not define 
pathophysiological entities. It is plausible that a focus on components would be valuable (e.g.,  
cognition, mood stability, or innate anxiety-fearfulness). The resolution of these issues will address 
major unanswered questions: from a genetic perspective, what are these disorders? How are they 
similar and how are they different?   
Common complaints  
Briefly, there are three common complaints about the work of the PGC. First, “the results don’t 
matter” – the readouts are broad with small effect sizes, and the effect sizes of individual associated 
loci are small. In fact, the results are delivering increasingly useful and targeted knowledge (discussed 
under Aim 1 above) (38, 39, 46). The small effect sizes do not constrain the potential  utility of targeting 
the identified genes or pathways – drugs targeting those pathways can have  major effects. Unlike 10 
years ago, pharmaceutical companies are following this area closely as genomic data are increasingly 
crucial to drug development (40).   
Second, “what about unaccounted heritability (h
2
)?” Heritability estimated from genome-wide SNP 
data (SNP-h2) depends on technical issues and sample size. The comparator is estimated from twin  or 
family data (twin-h2 or pedigree-h2), but these are assumption-laden and  imprecise. “Unaccounted h
2
” 
is the difference between these, and attempts to reconcile two fundamentally different entities. Still, 
when the genomic study is sufficiently large as with schizophrenia, SNP-h2 is around half of the 
pedigree-h2. A point often missed, however, is that explaining h2 is a minor goal. The main goals of the 
PGC are to gain biological, clinical, and therapeutic insights, which can arise regardless of the 
magnitude of heritability accounted for.   
Third, because most PGC analyses are based on categorical, case vs control analyses, “PGC cases lack 
clinical depth”. This was by intention: over 10 years ago (37), some of us reasoned that fast phenotype 
characterization that led to affordably large sample sizes was the logical first step (as opposed to large 
numbers of phenotypes on small numbers of subjects). This was always the first step. The success of 
this strategy is seen, not only in the genome-wide significant loci that we have discovered, but also in 
the many phenotypes that have been associated with PGC GRS in both clinical and population samples. 
The second step, ongoing now, is detailed characterization of genetically informative subsets of cases 
(e.g., Aim 2). In addition, some PGC working groups (e.g., Substance Use Disorders) are currently 
analyzing quantitative phenotypes.  
Conclusion  
The PGC is the largest and most systematic genomics effort in the history of psychiatry. In the next five 
years, we propose to markedly up-scale our work. By tackling nature as it is and not as we might want 
it to be, we hope to provide considerable new knowledge about the fundamental basis of psychiatric 
disorders. Our long-standing commitment to global collaboration, open science, and rapid progress 
means that we will make our results and tools available in a timely  manner. Prediction of the future 
is always hazardous but, given that we finally have a minimally adequate toolkit for genomics, it is 
possible that we are entering a golden age of research into the fundamental basis of severe mental 
illness.  
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PGC background data  
• In continuous existence from 2007 to the present  • International, over 800 scientists from 40 countries  • The nine PGC working groups study: attention-deficit hyperactivity disorder, autism, bipolar disorder, eating 
disorders, major depressive disorder, obsessive-compulsive disorder/Tourette syndrome, post- traumatic 
stress disorder, schizophrenia, and substance use disorders. Provisional groups for anxiety disorders and 
Alzheimer’s disease were added in 2016  • Current goals are to obtain genome-wide association data on 100,000 cases for each disorder  • Includes groups focused on cross-disorders analysis, copy number variation, statistical analysis, pathway 
analysis  • The PGC has published 24 main papers and 51 secondary analysis papers (Table S1). At least 141  
papers have made use of PGC results. PGC core 
principles  
• Given the human, medical, and societal impact of psychiatric disorders, the PGC is passionate about  
rapid progress, and is a world leader in data and results sharing  
• Open, inclusive, participatory, and democratic science  • Core PGC activities are commercially “pre-competitive”: identifying the genomic results is a public good, and 
part of the fundamental characterization of these psychiatric disorders  • Rigorous methodology, commitment to producing robust, replicable, and secure findings. Strong  
empirical focus, healthily questioning of prior knowledge and assumptions  
“Mega-analysis” framework: PGC members share raw genotype data so that all samples can be processed using a uniform 
quality control, imputation, and analysis pipeline 
 
PGC group  Ncase   Hits  
 
2 
Twin-h    
 
2 
SNP-h    Strongest genetic correlation  
Schizophrenia  60,995  155  81%  45%  Bipolar disorder  
MDD   130,664  20+  30-40%  14%  Neuroticism  
Bipolar disorder  20,352  19  80%  21%    
ADHD  20,183  12  70-80%  22%  Educational attainment  
Autism spectrum disorder  18,381  3  75%  12%  Subjective well-being  
Anorexia nervosa  3,495  1  56%  ~20%  Metabolic traits  
Substance use disorders  3,772  1  50%  ~10%  Smoking  
Tourette syndrome  4,232  1  60-80%  58%  OCD  
OCD  2,688  0  45-65%  37%  Tourette syndrome  
PTSD  3,749  0  30-40%  5-35%  Schizophrenia  
 
Common genetic variation: continue & expand ongoing work of the PGC to increase knowledge.   
SNPs. (a) The core business of the PGC: progressively larger GWAS mega-analyses for all disorders studied by the PGC. (b) 
Systematic cross-disorder analyses. (c) Pathway analyses to clarify biological implications. Critically, we have engaged 
academic and industry experts in psychopharmacology  to  maximize therapeutic implications of the findings.   
Genetic risk scores (GRS). (a) Development: use data from large longitudinal cohorts to evaluate the developmental 
effects of GRS. (b) Clinical symptoms: analyze relationship between clinical descriptors and GRS to understand clinical 
relevance. (c) GxE: analyze GRS x environment interactions.   
  
 
2 
2 
Brainstorm initiative. Apply novel statistical methods to GWAS results to estimate pairwise genetic correlations 
among all PGC disorders and with all obtainable CNS-relevant diseases/quantitative traits (e.g., epilepsy, 
neuroimaging, personality, IQ) to develop a comprehensive portrait of genetic influences across a broad set of brain 
phenotypes.   
Rare variation: enhance discovery of alleles with larger effects on risk.   
CNVs. Analyze rare CNVs in all PGC disorders via high-quality mega-analyses, and perform cross-disorder analyses to reveal 
pleiotropic genetic effects.   
Sequencing. Characterize the full spectrum of genetic variation for SCZ (especially rare variants of strong effect) in regions 
implicated in Aim 1. Inexpensively sequence coding and regulatory regions of ~200 candidate genes in 20,000 independent 
subjects.   
Pedigree sequencing. The large network of PGC clinicians has identified unusual pedigrees densely affected with 
psychiatric disorders. Systematically evaluate ~100 pedigrees for CNVs, high levels of GRS, and whole genome sequencing 
to enable searches for rare variants of strong effect.   
 
Table 1a. PGC background information and core principles (URLs).   
Table 1b. Update, current findings for each PGC working group. Ncase=number of cases. Hits=independent 
associations reaching genome-wide significance. Twin-h =heritability estimated from twin studies. SNP-h 
=heritability estimated from GWAS results.   
Table 1c. Current projects for the PGC.   
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Figure 1a. Statistical power. Upper curve (blue) shows minimum detectable genotypic relative risks for common 
variants for 1,000 cases and 1,000 controls (90% power, additive model, lifetime risk 0.01, α=5e-8). Lower curve (red) 
shows 90% power for the PGC 2014 schizophrenia paper (37,000 cases and 113,000 controls, additive model, lifetime 
morbid risk 0.01, α=5e-8). Black dots show the top 10 loci in the PGC schizophrenia report. These loci are highly 
significant with P-values ranging from 1.7e-13 to 3.8e-32.   
Figure  1b. Odds  ratios  (OR,  log10)  and  allele  frequencies  from  published  GWAS.  From EBI-NHGRI  GWAS  catalog 
(URLs,   accessed   1/27/2017),   contains   2,308   GWAS   published   3/2005-7/2016.   There   are   9,485   SNP-trait  
associations (P ≤ 1e-8) including 7,487 SNPS and 870 traits. Dots show frequency and OR (OR transformed to be >1 
and allele frequencies to 0-0.50). Contours show densest areas of the plot. Horizontal lines show 50
th
 (1.22) and 90
th
 
(1.95) percentiles for ORs: most associations are subtle. Of 62 associations with OR>5, most are for infectious  
disease   (31;   e.g.,   influenza   susceptibility),   pharmacogenomic   (13;   e.g.,   rare   adverse   drug   reactions   like 
flucloxacillin-induced liver injury), eye disease (4; e.g., glaucoma), or pigmentation (2; e.g., blue vs. brown  eyes). Only 
a few diseases have atypically large ORs (e.g., celiac disease, melanoma, membranous nephropathy, myasthenia 
gravis, ovarian cancer, Parkinson's disease, progressive supranuclear palsy, thyrotoxic hypokalemic periodic paralysis, 
and type 1 diabetes). The only psychiatric finding was alcohol consumption and ALDH2 in individuals of East Asian 
ancestry. 
  
 
 
 
  
Figure 2a. Genetic causes of severe intellectual disability (ID) (50), autism spectrum disorder (51, 52), and 
schizophrenia (53), including copy number variation (CNV), inherited known recessives, and single nucleotide variants 
(SNV). For severe ID, most SNV and CNV are de novo. The unknown grouping includes common variation, 
undiscovered rare genetic causes, phenocopies, and causation due to non-genetic effects.   
Figure  2b. Significant genetic associations for  schizophrenia.  Y-axis is log10  of odds ratio.  X-axis is  log10  of  allele 
frequency in controls. Odds ratios transformed to be >1 and frequencies to be ≤ 0.5. The dots on the lower right 
(cyan) shows common-variant associations for schizophrenia (P<1e-8) (14). Open diamonds (red) show copy number 
variation associated with schizophrenia (29). Filled square (green) shows the lone variant identified using whole 
exome sequencing (30).   
 
 
 
 
 
MDD=major depressive disorder, SCZ=schizophrenia, ED=eating disorders, OCD/TS=obsessive-compulsive 
disorder/Tourette syndrome, PTSD=post-traumatic stress disorder, and SUD=substance use disorders.   
Figure 3b. Relation between numbers of cases and genome-wide significant SNPs in GWAS. Lines show discovery paths 
for inflammatory bowel disease (IBD), schizophrenia (SCZ), height, and bipolar disorder (BIP). IBD has an exceptional 
genetic architecture and excellent clinical diagnostic specificity that enabled  considerable discovery with relatively 
smaller numbers of cases. SCZ, height, and BIP follow more typical and  approximately  similar discover paths   
  
Figure 3c. Hypothetical cartoon of the relation between number of cases and genome-wide significant associations for 
a human complex disease or trait. Complexities arising from the true nature of the initially unknown genetic 
architecture could change the form of this curve importantly. There is an initial dead zone whose length depends how 
many cases are accrued and the largest effect size. This is followed by an inflection point where the significant 
associations begin to accumulate and then a linear phase.   
 
  
  
 
 
  
  
  
  
 
  
  
  
  
  
 
 
 
  
  
 
  
 
 
 
  
 
  
 
 
 
